Autoimmune Disease vs. Ankylosing Spondylitis: Understanding the Overlap

Introduction

Is ankylosing spondylitis an autoimmune disease? The honest answer is not exactly. Ankylosing spondylitis (AS) can be said to be between autoimmune and autoinflammatory disease. It is a differentiation which researchers are still actively working on. It is a fact that most patients are surprised, since rheumatologists and pamphlets often use the word “autoimmune” at the time of diagnosis without explaining what it means for this specific condition.

This matters more than the words used. Understanding where AS fits, and where it genuinely overlaps with other immune-related conditions, changes how you read about your own symptoms and how you talk to your rheumatologist. This article talks about what makes a disease autoimmune, where ankylosing spondylitis breaks that pattern, how it compares directly to rheumatoid arthritis, and which conditions actually do occur alongside it.

Ankylosing spondylitis is not rare in India, but it remains poorly tracked and often misunderstood, even by patients who have lived with it for years.

A pooled, age-and-sex-adjusted analysis of Indian population survey by Indian Journal of Rheumatology estimated AS prevalence at just 0.03%, while the broader spondyloarthritis family of conditions, which includes AS, affects roughly 7 to 9 per 10,000 people. HLA-B27, the genetic marker most strongly linked to AS, appears in only about 6% of the general Indian population, yet shows up in more than 90% of Indian patients diagnosed with AS.

The gap between a rare marker in the population and its near-universal presence in diagnosed patients itself suggests that AS in India is likely underdiagnosed rather than genuinely rarer. This is what exactly we will talk about in this article.

What Actually Makes a Disease “Autoimmune”?

An autoimmune disease develops when the immune system produces antibodies that mistakenly attack the body’s own tissue. These self-targeting proteins are called autoantibodies, and a blood test can usually detect them directly.

Rheumatoid arthritis (RA) is the clearest example. Most RA patients test positive for specific autoantibodies, rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP), and these antibodies directly attack the tissue lining the joints. Lupus and type 1 diabetes follow a similar pattern, each driven by antibodies that target a specific part of the body.

This mechanism gives doctors a clear diagnostic path. A positive RF or anti-CCP result, combined with the right symptoms, confirms the autoimmune process directly, rather than relying on inference from imaging or symptom patterns alone. That test result also helps guide treatment, since medications for antibody-driven disease target the immune cells producing those antibodies.

That definition is clean, testable, and widely understood. It is also the exact definition in which ankylosing spondylitis does not fully fit.

Why Ankylosing Spondylitis Does Not Fit the Textbook Definition

Unlike RA, ankylosing spondylitis has no confirmed autoantibodies. No blood test finds a self-attacking antibody the way RF or anti-CCP testing does for RA, which is one reason AS diagnosis relies so heavily on imaging and clinical patterns rather than a single lab result. This gap led researchers to examine whether AS fits a second category: autoinflammatory disease.

Autoinflammatory conditions involve the body’s general-purpose immune defenses overreacting, without antibodies specifically targeting self-tissue the way classic autoimmune disease does. A 2021 review in Nature Reviews Rheumatology examined the evidence on both sides and found that AS shows genuine hallmarks of each process, rather than sitting cleanly in either box.

The strongest genetic clue in AS is a gene called HLA-B27, present in a large majority of AS patients, though the exact figure varies by study and population, ranging from roughly three-quarters to over ninety percent across different cohorts. HLA-B27 affects how certain immune cells process and respond to threats, and that mechanism is part of why researchers still debate exactly where AS belongs on the autoimmune-to-autoinflammatory spectrum.

None of this makes AS a lesser or less serious diagnosis. It makes AS a distinct category of immune-mediated disease, one that current research has not fully settled into a single box yet.

For patients, this explains a common source of confusion at diagnosis. Being told you have an “autoimmune condition” without further explanation invites you to picture the antibody-driven process familiar with RA or lupus, then leaves you puzzled when your bloodwork never shows the antibodies those conditions are known for. Knowing that AS genuinely works differently, rather than assuming your bloodwork is somehow incomplete, removes one layer of unnecessary confusion from an already difficult diagnosis.

AS vs. RA: Two Diseases That Get Confused More Than They Should

Patients newly diagnosed with either condition often assume AS and RA are close cousins, since both fall under the broader umbrella of arthritis, and both cause chronic joint pain. The mechanisms behind them are different enough that a side-by-side comparison clears up most of the confusion quickly.

These differences are not academic. They explain why a friend’s Rheumatoid Arthritis treatment plan can look like nothing like an AS treatment plan, without either person receiving the wrong care.

The Overlap That Actually Matters: AS’s Real Autoimmune Companions

Now let’s talk about the overlap which actually matters. Though AS itself doesn’t fit the classic autoimmune definition, it frequently occurs alongside conditions that do, and this pattern shows consistently across large studies.

A UK population-based cohort study followed 4,101 AS patients matched against 28,591 people without AS. At the time of AS diagnosis, 11.4% of patients already had acute anterior uveitis, 4.4% had psoriasis, and 3.7% had inflammatory bowel disease.

Over the full course of the disease, a separate meta-analysis found those numbers climb further: uveitis reaches 22–37%, inflammatory bowel disease reaches 4–16%, and psoriasis reaches 4–9%, depending on the population studied.

So simply put:

• Uveitis is inflammation inside the eye
• Inflammatory bowel disease covers crohn’s disease and ulcerative colitis
• Psoriasis is a scaly, itchy skin condition that is itself autoimmune.

All three show up in AS patients far more often than in the general population.

The eye connection is worth pausing specifically, since it is the most common of the three and the easiest to miss. Uveitis can develop suddenly, with redness, pain, and light sensitivity in one eye, and it typically requires prompt treatment to avoid lasting vision damage. Patients who know this overlap exist are more likely to recognize the symptoms early and seek care quickly, rather than assuming it is unrelated to their joint condition.

Antardhwani’s panel rheumatologists, who lead the doctor-patient sessions featured on our YouTube channel, consistently point out this pattern. They ask about eye redness, digestive symptoms, or skin changes even when a patient’s main complaint is back pain. It is not an unrelated question. It is a targeted screen for a known overlap, built directly from the population data above.

Why This Distinction Changes How AS Actually Gets Treated

Because AS and RA involve different immune mechanisms, they often respond to different classes of medication. Treatment is also influenced by any overlap conditions the patient has, not just their joint symptoms alone.

The overlap conditions described above also shape treatment choices directly. A TNF inhibitor prescribed for AS, for instance, often helps manage co-occurring inflammatory bowel disease at the same time, since the two conditions share inflammatory pathways. This is one reason your rheumatologist may adjust medication choice based on which overlap conditions you have, not only on your joint symptoms alone.

This is worth knowing before you compare notes with another patient. A treatment plan that looks completely different from someone else’s isn’t a sign that either of you is receiving the wrong care; it reflects two genuinely different diseases, sometimes with different overlap conditions layered on top.

What This Means If You’re A Newly Diagnosed patient, or Still Waiting for Reports

A diagnosis, or the wait for one, comes with real uncertainty. Before your next appointment, three things are worth carrying with you, regardless of where you are in that process. Each one addresses a specific worry patients raise most often, and each one is grounded in the science covered above.

• You do not need to test positive for autoantibodies for your pain to be real or your diagnosis to be valid.
• Ask your doctor specifically about eye, skin, and digestive symptoms, even if they seem unrelated to your back pain, since these are the overlap conditions the research above shows up most often.
• A negative HLA-B27 test does not rule AS out on its own, since diagnosis relies on a broader clinical picture that includes imaging, symptom pattern, and family history together.

None of this replaces a direct conversation with a specialist who knows your full medical history and test results. If you want to talk through your specific symptoms or simply hear how other patients navigated this same uncertainty, both options are one click away below.

Want to talk through your specific symptoms or test results with our team?

Hear how other patients made sense of their diagnosis, including overlap symptoms they didn’t expect. Watch patient stories on